Women's Health
Research at Yale
PO Box
208091
New Haven, CT 06520-8091
Tel: 203.764.6600
Fax: 203.764.6609
whresearch@yale.edu
Women’s Health Research at Yale supports clinical trials that are generating new and useful scientific knowledge about women's health and gender differences. The following clinical trials are currently recruiting subjects.
The “intervention group” is closed to enrollment. Dr. Barbara Gulanski is currently seeking healthy, normal weight, non-smoking, post-menopausal women between 40 and 65 years of age as a “comparison group” for her research on cardiovascular health. Study participants must not be taking estrogen or cholesterol lowering medications. Two visits to the Yale New Haven Hospital General Clinical Research Center for a variety of non-invasive tests are required. Results shared with participants. Participants are not compensated. Interested volunteers may contact Laurie at (203) 764-6623. (Protocol # 25094)
[CLOSE]Osteoporosis and low bone mineral density affect almost 44 million Americans over the age of 50 years, most of whom are women, and this number is expected to grow to 52 million by the year 2010. Dr. Karl Insogna at the Yale School of Medicine is investigating the possible benefit of a protein supplement on bone health in postmenopausal women. We are asking healthy women over the age of 60, who naturally consume a diet low to moderate in protein, to participate in our study, which will begin in early 2007. Study participants must not have osteoporosis or other bone disease and may not be taking estrogen or other medications to prevent bone loss. After an initial screening examination, bone density test and blood work, eligible participants will be randomized to take either a 40-gram protein or placebo supplement daily for 18 months. The protein or placebo supplement will be incorporated into your usual diet and it is expected that your weight will remain stable over the course of the study. Study visits will occur every 3 months and study participants can choose to be followed at either of the two study sites for this trial which are, the Yale University Clinical Research Center in New Haven, CT and the University of Connecticut Health Center in Farmington, CT. During the course of this trial participants will receive free bone density testing, nutritional counseling and health screening. If you are interested, please call the Recruitment Center toll-free at 1-866-846-2849. Help us find alternative, safe and effective therapies for the prevention of osteoporosis! (Protocol # 0610001951)
[CLOSE]Women chart their symptoms for one menstrual cycle to confirm a diagnosis of moderate Premenstrual Syndrome. Participants are asked to participate in one of the treatment conditions (Serafem, Calcium or placebo); all participants receive Calcium at some point during the 7-month long study. Typical PMS symptoms could include: fluxuations in mood, such as sadness, anger, anxiety and/or irritability; difficulty concentrating or making decisions; disruption in sleep or appetite; functional impairment in work/home/relationship domains; physical symptoms. Treatment services are free and confidential and available in English and Spanish in our New Haven, CT office. Participants are not compensated. Kimberly Yonkers, M.D. is the Principal Investigator for this trial. Please call (203)764-6621 to participate or visit our website at www.researchforher.com for more information.
[CLOSE]Healthy women age 42-58, who have not had their periods for at least 6 months and less than 3 years, will be randomly assigned to hormone therapy or placebo. Site Principal Investigator: Hugh Taylor, M.D.; GCRC Principal Investigator: Barbara Gulanski, M.D., M.P.H. Subjects will be compensated for their participation. Please call Diane at (203) 785-4739. (Protocol # 27022) (KEEPS: Kronos Early Estrogen Prevention Study)
[CLOSE]This project seeks women with coronary artery disease to participate in either of two studies which will include testing of heart and brain function using noninvasive imaging equipment. Participants will receive financial compensation. Principal Investigator: Robert Soufer, M.D. Please call Christine Earley at (203) 932-5711, Ext. 3332; or Luisa Sheehan at (203) 932-5711, Ext. 2839 (Yale University School of Medicine HIC Protocol #s: 9256 & 22874; VA Connecticut Healthcare System HSS Protocol #s: RS0017 & RS0018)
[CLOSE]Previous work by our group has demonstrated abnormally low levels of the brain chemical (gamma-amino butyric acid or GABA) in depressed individuals. MRS uses magnetic fields and radio waves, similar to magnetic resonance imaging (MRI). But, rather than visualizing the brain, MRS is able to measure the levels of several chemicals and neurotransmitters in the brain. GABA levels in depressed patients are assessed before and after various kinds of treatment for depression, such as cognitive behavioral therapy (see below) or different kinds of medications, to determine whether GABA levels are abnormal in depression and if different treatments have an effect on this chemical. Principal Investigator: Gerard Sanacora, M.D., Ph.D. Call the Yale Depression Research Program at (203) 764-9131 or email gerard.sanacora@yale.edu. (Yale University School of Medicine HIC Protocol # HIC# 12812)
[CLOSE]Depressed individuals often have negative opinions of themselves and tend to have negative interpretations of events as well as negative expectations for the future. These kinds of thought patterns increase an individual's risk of developing or maintaining depression when they experience stressful life events. The use of CBT to alter these cognitive patterns has proven effective in the treatment of depression. This study provides twelve weeks of CBT for the treatment of depression at no cost. It also uses a non-invasive technique to measure levels of neurotransmitters in the brain before and after treatment by obtaining magnetic resonance spectroscopy measures (MRS - see above). These MRS measures, as well as other assessments in this study, may help us to understand which individuals are likely to respond to treatments such as cognitive behavioral therapy. Principal Investigator: Gerard Sanacora, M.D., Ph.D. Call the Yale Depression Research Program at (203) 764-9131 or email gerard.sanacora@yale.edu. (Yale University School of Medicine HIC Protocol # HIC# 26807)
[CLOSE]ECT provides benefit for many individuals suffering from severe medication-resistant depression, but many patients whose depression improves following ECT experience a relapse of symptoms within the six months following their treatment. This study hopes to determine if combining these two treatments could increase the benefits of ECT and prolong the period of remission from depression brought about by ECT. Principal Investigator: Gerard Sanacora, M.D., Ph.D. Call the Yale Depression Research Program at (203) 764-9131 or email gerard.sanacora@yale.edu. (Yale University School of Medicine HIC Protocol # HIC# 12500)
[CLOSE]Participants in this study who suffer from panic disorder or GAD will receive 13-18 weeks of CBT targeted at their anxiety disorder, free of cost. They will also undergo measures of Magnetic Resonance Spectroscopy (MRS - see above) to measure levels of certain neurotransmitters in the brain. These MRS measures may help us to understand which individuals are likely to respond to treatments such as cognitive behavioral therapy and what effect this type of therapy may have on these brain chemicals. Principal Investigator: Gerard Sanacora, M.D., Ph.D. Call the Yale Depression Research Program at (203) 764-9131 or email gerard.sanacora@yale.edu. (Yale University School of Medicine HIC Protocol # HIC# 25397)
[CLOSE]Subjects in this study will receive 12 weeks of Riluzole treatment added on to their existing medications and will meet weekly with a psychiatrist in the clinic in order to better understand the effects of this novel treatment on the symptoms of depression. Principal Investigator: Gerard Sanacora, M.D., Ph.D. Call the Yale Depression Research Program at (203) 764-9131 or email gerard.sanacora@yale.edu. (Yale University School of Medicine HIC Protocol # HIC# 15638)
[CLOSE]Participants will receive several measures of Magnetic Resonance Spectroscopy (MRS - see above) to assess neurotransmitter levels both before and after a short dose of this novel treatment. Following this brief trial, participants will also receive 6 weeks of treatment with a serotonin reuptake inhibitor (SSRI) free of charge. Principal Investigator: Gerard Sanacora, M.D., Ph.D. Call the Yale Depression Research Program at (203) 764-9131 or email gerard.sanacora@yale.edu. (Yale University School of Medicine HIC Protocol # HIC# 26997)
[CLOSE]These genetic studies could help in the understanding of the genes that contribute to the development of depression [HIC # 25410] and may uncover how the expression of these genes might predict response to antidepressant treatment. Principal Investigator: Gerard Sanacora, M.D., Ph.D. Call the Yale Depression Research Program at (203) 764-9131)
[CLOSE]The MDRP brings together a multi-disciplinary group of scientists who use a wide variety of research methods in a highly collaborative research effort to study the genetic and environmental factors that contribute to mood disorders, and how these factors interact to affect the brain and cause the specific symptoms associated with these disorders.
In ongoing research, MDRP scientists are working towards the development of biological markers that can help to determine if someone has a mood disorder, and if they do, what treatment might be most beneficial to them. We hope that these research efforts will lead to new and improved methods for the prevention, early detection and treatment of mood disorders. - MDRP Director, Hilary P. Blumberg, M.D.
For more information on clinical trials, visit the mood disorder webpage: www.mood.yale.edu
We are seeking healthy adults between 18 and 55 years of age, who regularly smoke at least ½ pack of cigarettes a day, and who wish to quit smoking. Participants must be medically healthy and not dependent on alcohol or drugs. No medications can be taken during the study. If eligible for our study, participants will join a 4-week smoking cessation study and meet with a study coordinator for supportive therapy and advice on quitting and maintaining smoking abstinence. First week includes daily appointments, support and increasing payments to reward success. Second week includes three appointments, telephone support and payment for study visits. During third and fourth weeks, two follow-up appointments and telephone support if desired. Participants can earn up to $640 for attending all study visits and maintaining abstinence from smoking. Principal Investigator: Ann Rasmusson, M.D. Please call Eleni Dimoulas, Ph.D. at (203) 932-5711, extension 5015. (Yale University School of Medicine HIC Protocol # HIC# 19974; VA Connecticut Healthcare System HSS Protocol #: AR0020)
[CLOSE]Suniya S. Luthar, Ph.D., Professor of Clinical and Developmental Psychology, Teachers College, Columbia University is examining how mothers feel not only as parents but also as thinking, feeling and working individuals. This survey will help explore how mothers feel about their different roles not only as a mother, but also as a spouse, as a friend and an individual with various hopes and fears and how they cope with the challenges of balancing multiple roles. On average the survey takes 30-35 minutes to complete. It will be completely anonymous, such that there are no questions that will identify or link the data to any individual. Visit: http://www.momsaspeople.com/ Results of the survey will be compiled and posted on the web site. (IRB # 07-006)
[CLOSE]This study is for adults (ages 18-75) who are currently interested in quitting smoking. Participants in this 9 week trial will be randomly assigned to receive either selegiline or placebo. All participants will receive brief weekly individual counseling for smoking cessation and be asked to fill out research questionnaires. Subjects will be compensated for their participation. Principal Investigator: Marc N. Potenza, M.D., Ph.D. Please contact Erin at (203) 974-STOP (203-974-7867) or visit http://prism.yale.edu. (Protocol #26091)
[CLOSE]
©
Yale School of Medicine
Last updated
6/27/07
Privacy policy Site editor
